Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 TrialCiara Louise Freeman, Matthew J. Frigault, Carolina Schinke et al.|Blood|2024Cited by 20
Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: Updated results from iMMagine–1Krina Patel, Matthew J. Frigault, Binod Dhakal et al.|Blood|2025Cited by 8
Phase 2 Registrational Study of Anitocabtagene Autoleucel for Relapsed and/or Refractory Multiple Myeloma (RRMM): Updated Results from iMMagine-1Gurbakhash Kaur, Matthew J. Frigault, Ciara L. Freeman et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0